The effect of age on the severity of dry mouth occurring in patients receiving high dose radioactive iodine treatment

Yıl 2023, Cilt: 6 Sayı: 4, 775 - 779, 30.07.2023

Veysel Eratilla , İhsan Kaplan

https://doi.org/10.32322/jhsm.1285641

Cited By: 1

Öz

Aims: Dry mouth of individuals causes many oral discomforts and undesirable conditions. In order to prevent such an undesirable situation from occurring, it is aimed to complete the Radioactive Iodine Therapy (RAI) treatment with less damage by mastering all possible factors. In our study, we aimed to find the level of the effect of the age factor.
Methods: In this study, we included patients who received high-dose radioactive iodine treatment after total thyroidectomy for differentiated thyroid cancer and were hospitalized in our clinic. These patients were selected among the patients who applied to our hospital between 2021-2022. We specifically focused on patients who reported dry mouth and obtained salivary gland scintigraphies of their submandibular glands. Afterwards, we looked at the ratio of the age of the patients with the level of dry mouth. We analyzed the collected data using statistical methods.
Results: The data analysis was performed using the Chi-square (χ2) test and the Spearman correlation test to examine the relationship between age and the severity of dry mouth in patients undergoing high-dose RAI treatment for thyroid cancer. Our hypotheses were two-sided, and statistical significance was considered at p-values ≤0.05. The results of our analysis revealed that there was no significant direct correlation between age and the severity of dry mouth in the patients. This suggests that age is not a determining factor for the occurrence or severity of dry mouth in individuals receiving high-dose RAI treatment.
Conclusion: In our study, it was concluded that the age factor alone was not a determining factor in terms of the severity of dry mouth. Therefore, it is important to consider additional factors and potential underlying causes when evaluating and managing dry mouth in patients receiving high-dose RAI therapy for thyroid cancer.

Anahtar Kelimeler

Dentistry, dry mouth, age

Kaynakça

• Bergdahl M, Bergdahl J. Low unstimulated salivary flow and subjective oral dryness: association with medication, anxiety, depression, and stress. J Dent Res. 2000;79(9):1652-1658. doi:10.1177/00220345000790090301
• Porter SR, Scully C, Hegarty AM. An update of the etiology and management of xerostomia. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2004;97(1):28-46. doi:10.1016/j.tripleo.2003.07.010
• Son SH, Lee CH, Jung JH, et al. The preventive effect of parotid gland massage on salivary gland dysfunction during high-dose radioactive iodine therapy for differentiated thyroid cancer: a randomized clinical trial. Clin Nucl Med. 2019;44(8):625-633. doi:10.1097/RLU.0000000000002602
• Scully C, Sonis S, Diz PD. Oral mucositis. Oral Dis. 2006;12(3):229-241. doi:10.1111/j.1601-0825.2006.01258.x
• Eratilla V. Investigation of parotid gland function changes caused by dry mouth in patients receiving high-dose radioactive iodine treatment. Int J Basic Clin Stud. (IJBCS). 2021;10:66-74
• Eratilla V, Doğan MS, Eratilla E. Seroprevalence of hepatitis and HIV in people admitted to Diyarbakir state hospital. J Harran Uni Med Faculty. 2018;15:241-44.
• Diamond-Rossi SA, Jonklaas J, Jensen RE, et al. Looking under the hood of "the cadillac of cancers:" radioactive iodine-related craniofacial side effects among patients with thyroid cancer. J Cancer Surviv. 2020;14(6):847-857. doi:10.1007/s11764-020-00897-5
• Assy Z, Bots CP, Arisoy HZ, Gülveren SS, Bikker FJ, Brand HS. Differences in perceived intra-oral dryness in various dry-mouth patients as determined using the Regional Oral Dryness Inventory. Clin Oral Investig. 2021;25(6):4031-4043. doi:10.1007/s00784-020-03734-2
• Al Hamad A, Lodi G, Porter S, Fedele S, Mercadante V. Interventions for dry mouth and hyposalivation in Sjögren's syndrome: A systematic review and meta-analysis. Oral Dis. 2019;25(4):1027-1047. doi:10.1111/odi.12952
• Bielfeldt S, Wilhelm D, Neumeister C, Schwantes U, Wilhelm KP. Effect of a newly developed pastille on the salivary flow rate in subjects with dry mouth symptoms: a randomized, controlled, monocentric clinical study. BMC Oral Health. 2021;21(1):117. Published 2021 Mar 12. doi:10.1186/s12903-021-01471-w
• Heiskanen V, Zadik Y, Elad S. Photobiomodulation therapy for cancer treatment-related salivary gland dysfunction: a systematic review. Photobiomodul Photomed Laser Surg. 2020;38(6):340-347. doi:10.1089/photob.2019.4767
• Solans R, Bosch JA, Galofré P, et al. Salivary and lacrimal gland dysfunction (sicca syndrome) after radioiodine therapy. J Nuclear Med. 2001;42(5):738-743.
• Park KW, Wu JX, Du L, Leung AM, Yeh MW, Livhits MJ. Decreasing use of radioactive iodine for low-risk thyroid cancer in California, 1999 to 2015. J Clin Endocrinol Metab. 2018;103(3):1095-1101. doi:10.1210/jc.2017-02269
• Singer MC, Marchal F, Angelos P, et al. Salivary and lacrimal dysfunction after radioactive iodine for differentiated thyroid cancer: American Head and Neck Society Endocrine Surgery Section and Salivary Gland Section joint multidisciplinary clinical consensus statement of otolaryngology, ophthalmology, nuclear medicine and endocrinology. Head Neck. 2020;42(11):3446-3459. doi:10.1002/hed.26417
• Kim DW. Ultrasonographic features of the major salivary glands after radioactive iodine ablation in patients with papillary thyroid carcinoma. Ultrasound Med Biol. 2015;41(10):2640-2645. doi:10.1016/j.ultrasmedbio.2015.06.010
• Jeong SY, Kim HW, Lee SW, Ahn BC, Lee J. Salivary gland function 5 years after radioactive iodine ablation in patients with differentiated thyroid cancer: direct comparison of pre- and postablation scintigraphies and their relation to xerostomia symptoms. Thyroid. 2013;23(5):609-616. doi:10.1089/thy.2012.0106
• Caglar M, Tuncel M, Alpar R. Scintigraphic evaluation of salivary gland dysfunction in patients with thyroid cancer after radioiodine treatment. Clin Nucl Med. 2002;27(11):767-771. doi:10.1097/00003072-200211000-00003
• Van Nostrand D. Sialoadenitis secondary to ¹³¹I therapy for well-differentiated thyroid cancer. Oral Dis. 2011;17(2):154-161. doi:10.1111/j.1601-0825.2010.01726.x
• Riachy R, Ghazal N, Haidar MB, Elamine A, Nasrallah MP. Early sialadenitis after radioactive iodine therapy for differentiated thyroid cancer: prevalence and predictors. Int J Endocrinol. 2020;2020:8649794. doi:10.1155/2020/8649794